Clear ×
Dare Bioscience, Inc. DARE

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 11, 2026 8-K 1 signal fired
Other
Equity Plan Board Approval Conditional On Shareholder Vote
Aug 17, 2026 8-K 31 signals fired · top 15
Other
Corporate Organization And Standing Representation New York Jurisdiction Clause Market Price Definition Auditor Appointment Ratification Covenant Compliance Affirmation Ipo Net Proceeds Disclosure Amendment Modification Waiver Clause Corporate Authority Representation Form S3 Shelf Registration Disclosure Institutional Investment No Broker Fees Representation Registration Rights Piggyback Provision Use Of Proceeds Disclosure Warrant Exercise Share Delivery Fcpa Compliance Representation
Aug 13, 2026 10-Q 35 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Net Loss Reported Liquidity Position Snapshot Disclosed Cash Flow Statement Investing Activities Nasdaq Minimum Bid Price Delisting Notice Section 409A Compliance Statement Financing Activities Cash Flow Disclosure Capital Raising Uncertainty Disclosed Fair Value Hierarchy Reconciliation Disclosed Protocol Amended Sga Expense Comparison Disclosed Equity Plan Amendment Restriction Ipo Net Proceeds Disclosure
Core
Secondary Endpoint Mentioned Clinical Trial Result
Aug 13, 2026 8-K 9 signals fired
Core
Lead Asset Progress Clinical Trial Result Indication Expansion Clinical Hold Patient Enrollment Velocity
Other
Interim Data Positive Enrollment Ahead Of Schedule Personnel Cost Decrease Disclosure Expanded Access Program Active
Jul 17, 2026 8-K 1 signal fired
Other
Nasdaq Minimum Bid Price Delisting Notice
Jun 12, 2026 8-K 6 signals fired
Other
Say On Pay Vote Result Disclosed Equity Plan Board Approval Conditional On Shareholder Vote Ltip Plan Title Citation Auditor Appointment Ratification Adjournment Proposal Voting Requirement Equity Plan Share Reserve Disclosure
May 14, 2026 10-Q 33 signals fired · top 15
Other
Liquidity Position Snapshot Disclosed Net Loss Reported Nasdaq Minimum Bid Price Delisting Notice Sga Expense Comparison Disclosed Cash Flow Statement Investing Activities Fair Value Hierarchy Reconciliation Disclosed Ipo Or Capital Raising Completion Other Income Expense Disclosure Ipo Net Proceeds Disclosure Institutional Investment Convertible Debt Conversion Financing Activities Cash Flow Disclosure
Biotech Risk
Accelerated Approval
Core
Clinical Trial Result Indication Expansion
May 14, 2026 8-K 12 signals fired
Other
Ceo Team Pride Statement Patient Retention High Liquidity Position Snapshot Disclosed Administrative Efficiency Personnel Cost Decrease Disclosure Interim Data Positive
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Indication Expansion Clinical Hold
Biotech Risk
Clinical Hold Active
Apr 17, 2026 8-K 1 signal fired
Other
Classified Board Director Election